PMS-LOPERAMIDE - CAPLET 2MG TABLET

Nazione: Canada

Lingua: inglese

Fonte: Health Canada

Principio attivo:

LOPERAMIDE HYDROCHLORIDE

Commercializzato da:

PHARMASCIENCE INC

Codice ATC:

A07DA03

INN (Nome Internazionale):

LOPERAMIDE

Dosaggio:

2MG

Forma farmaceutica:

TABLET

Composizione:

LOPERAMIDE HYDROCHLORIDE 2MG

Via di somministrazione:

ORAL

Confezione:

100/500 CAPLETS

Tipo di ricetta:

OTC

Area terapeutica:

ANTIDIARRHEA AGENTS

Dettagli prodotto:

Active ingredient group (AIG) number: 0111332001; AHFS:

Stato dell'autorizzazione:

MARKETED

Data dell'autorizzazione:

1996-09-12

Scheda tecnica

_pms-LOPERAMIDE & pms-LOPERAMIDE HYDROCHLORIDE SOLUTION Product
Monograph _
_Page 1 of 38 _
_ _
PRODUCT MONOGRAPH
INCLUDING PATIENT MEDICATION INFORMATION
PMS-LOPERAMIDE
Loperamide Hydrochloride Tablets
Caplet, 2 mg, oral
USP
and
PMS-LOPERAMIDE HYDROCHLORIDE SOLUTION
Loperamide Hydrochloride Oral Solution
Solution, 0.2 mg / mL, Oral
USP
Antidiarrheal agent
PHARMASCIENCE INC.
6111 Royalmount Ave., Suite 100
Montréal, Canada
H4P 2T4
www.pharmascience.com
Date of Initial Authorization:
pms-LOPERAMIDE HYDROCHLORIDE SOLUTION:
June 2, 1993
pms-LOPERAMIDE
August 2, 1996
Date of Revision:
June 26, 2023
Submission Control Number: 272133
_pms-LOPERAMIDE & pms-LOPERAMIDE HYDROCHLORIDE SOLUTION Product
Monograph _
_Page 2 of 38 _
_ _
RECENT MAJOR LABEL CHANGES
5 OVERDOSAGE, Addition of drug withdrawal syndrome
06/2022
7 WARNINGS AND PRECAUTIONS, Addition of drug withdrawal syndrome
06/2022
TABLE OF CONTENTS
SECTIONS OR SUBSECTIONS THAT ARE NOT APPLICABLE AT THE TIME OF
AUTHORIZATION ARE NOT LISTED.
RECENT MAJOR LABEL CHANGES
.......................................................................................................
2
TABLE OF CONTENTS
.........................................................................................................................
2
PART I: HEALTH PROFESSIONAL INFORMATION
................................................................................
4
1
INDICATIONS
........................................................................................................................
4
1.1
Pediatrics
...........................................................................................................................
4
1.2
Geriatrics
............................................................................................................................
4
2
CONTRAINDICATIONS
...........................................................................................................
4
4
DOSAGE AND ADMINISTRATION
.....................................................................